Objectives To evaluate the incremental effectiveness of anaplastic lymphoma kinase (ALK) inhibitor lorlatinib compared to platinum-based chemotherapy (PBC) for adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) whose disease progressed after alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy or after crizotinib and at least one other ALK TKI in the Portuguese setting. Conclusions Lorlatinib results in increased life expectancy and quality-adjusted life expectancy compared with PBC in previously treated adult patients with ALK-positive NSCLC in the Portuguese setting. READ ARTICLE
Value in Health DOI:10.1016/j.jval.2020.08.205
Authors: R. Guerreiro, A.T. Paquete, L. Iadeluca, C. Almond, F. Albuquerque de Almeida, M. Inês, J. Costa, M. Borges, L. Silva Miguel,